Wall Street brokerages forecast that Quanterix Corp (NASDAQ:QTRX) will announce earnings per share (EPS) of ($0.36) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Quanterix’s earnings. The lowest EPS estimate is ($0.36) and the highest is ($0.35). Quanterix posted earnings of ($0.42) per share during the same quarter last year, which would indicate a positive year over year growth rate of 14.3%. The business is expected to report its next earnings results on Monday, March 16th.
According to Zacks, analysts expect that Quanterix will report full-year earnings of ($1.52) per share for the current financial year, with EPS estimates ranging from ($1.53) to ($1.51). For the next financial year, analysts anticipate that the firm will report earnings of ($1.59) per share, with EPS estimates ranging from ($1.67) to ($1.51). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Quanterix.
A number of analysts have weighed in on the company. Zacks Investment Research upgraded Quanterix from a “sell” rating to a “hold” rating in a research note on Wednesday, January 8th. Canaccord Genuity restated a “buy” rating and issued a $35.00 price target on shares of Quanterix in a research note on Thursday, November 7th. BidaskClub upgraded Quanterix from a “sell” rating to a “hold” rating in a research note on Friday, February 7th. Finally, ValuEngine cut Quanterix from a “buy” rating to a “hold” rating in a research note on Thursday, January 16th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $31.33.
In other news, Director Martin D. Madaus sold 1,600 shares of Quanterix stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $26.52, for a total transaction of $42,432.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP David C. Duffy sold 1,667 shares of Quanterix stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $22.56, for a total value of $37,607.52. Following the sale, the senior vice president now owns 46,427 shares in the company, valued at approximately $1,047,393.12. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 54,735 shares of company stock worth $1,337,041. 30.80% of the stock is owned by insiders.
Several institutional investors and hedge funds have recently bought and sold shares of QTRX. Metropolitan Life Insurance Co NY acquired a new stake in shares of Quanterix during the third quarter worth about $78,000. Citigroup Inc. increased its position in shares of Quanterix by 258.8% during the fourth quarter. Citigroup Inc. now owns 4,941 shares of the company’s stock worth $117,000 after purchasing an additional 3,564 shares in the last quarter. Alpine Global Management LLC acquired a new stake in shares of Quanterix during the fourth quarter worth about $207,000. Parametric Portfolio Associates LLC acquired a new stake in shares of Quanterix during the second quarter worth about $212,000. Finally, Royal Bank of Canada increased its position in shares of Quanterix by 116.4% during the second quarter. Royal Bank of Canada now owns 6,285 shares of the company’s stock worth $213,000 after purchasing an additional 3,380 shares in the last quarter. Institutional investors and hedge funds own 67.21% of the company’s stock.
Quanterix stock opened at $28.21 on Friday. Quanterix has a 1-year low of $19.08 and a 1-year high of $36.15. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.61 and a quick ratio of 7.00. The stock has a market cap of $786.94 million, a PE ratio of -16.89 and a beta of 1.27. The stock’s fifty day moving average is $25.10 and its two-hundred day moving average is $24.51.
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.
Featured Article: Resistance Level
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.